Scientists found that the simultaneously employment of TRAIL and the BCL-2 inhibitor venetoclax (VEN) could present a strong synergistic antileukemic activity in AML cells by stimulating extrinsic and intrinsic apoptosis signaling pathways [26]. Here, TNFSF10 is linked to acute myeloid leukemia.